Close Menu

NEW YORK (360Dx) – Interpace Diagnostics reported after the close of the market on Monday that its first quarter revenues rose 25 percent year over year.

For the three months ended March 31, the firm reported revenues of $6.0 million, up from $4.8 million in the year-ago quarter, but missed the consensus Wall Street estimate of $6.3 million.

Interpace President and CEO Jack Stover said in a statement that the firm had a strong start to the year, driven in part by increasing sales volumes for its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Holden Thorp is to be the new editor-in-chief of Science and its related journals.

Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.

A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.

In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.